[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Collegium Pharma (COLL)

Collegium Pharma (COLL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Collegium's Pain Portfolio Faces Its First Test Without Guidance

Collegium Pharmaceutical (NASDAQ: COLL) reports second-quarter 2026 earnings before the market opens on August 6, 2026. With the specialty pharmaceutical company having delivered a strong earnings beat last quarter and analysts expecting modest year-over-year growth, investors will be watching closely to see if COLL can maintain its recent momentum in the competitive pain management market.

Collegium Pharmaceutical is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of pain, with its flagship product Xtampza ER (extended-release oxycodone) serving as the primary revenue driver in the abuse-deterrent opioid market.

Fundamentals

See More
  • Market Capitalization, $K 1,158,867
  • Shares Outstanding, K 32,434
  • Annual Sales, $ 780,570 K
  • Annual Income, $ 62,870 K
  • EBIT $ 189 M
  • EBITDA $ 414 M
  • 60-Month Beta 0.73
  • Price/Sales 1.48
  • Price/Cash Flow 2.34
  • Price/Book 3.69

Options Overview Details

View History
  • Implied Volatility 57.00% (+2.04%)
  • Historical Volatility 31.49%
  • IV Percentile 45%
  • IV Rank 43.24%
  • IV High 88.16% on 03/11/26
  • IV Low 33.26% on 08/18/25
  • Expected Move (DTE 16) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 14
  • Put/Call OI Ratio 1.68
  • Today's Open Interest 1,145
  • Open Int (30-Day) 1,057
  • Expected Range 35.74 to 35.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.48
  • Number of Estimates 2
  • High Estimate $1.53
  • Low Estimate $1.42
  • Prior Year $1.47
  • Growth Rate Est. (year over year) +0.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.00 +5.12%
on 07/23/26
38.49 -7.16%
on 07/07/26
-1.29 (-3.48%)
since 07/02/26
3-Month
30.13 +18.62%
on 06/03/26
40.50 -11.75%
on 05/08/26
+0.42 (+1.19%)
since 05/05/26
52-Week
29.70 +20.34%
on 08/06/25
50.79 -29.63%
on 12/29/25
+4.64 (+14.92%)
since 08/05/25

Most Recent Stories

More News
Collegium's Pain Portfolio Faces Its First Test Without Guidance

Barchart Research What to Expect from COLL Earnings COLL Generated August 5, 2026 Current Price $35.74 EPS Estimate $$1.48 Consensus Rating Moderate Buy Average Move 4.85% Collegium's Pain Portfolio Faces...

COLL : 35.74 (+0.03%)
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect

Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect

COLL : 35.74 (+0.03%)
1 Cash-Producing Stock Worth Investigating and 2 We Ignore

1 Cash-Producing Stock Worth Investigating and 2 We Ignore

COLL : 35.74 (+0.03%)
GMED : 80.54 (-1.19%)
WOOF : 2.92 (-1.35%)
Winners And Losers Of Q1: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Branded Pharmaceuticals Stocks

Winners And Losers Of Q1: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Branded Pharmaceuticals Stocks

COLL : 35.74 (+0.03%)
Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026

STOUGHTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious...

COLL : 35.74 (+0.03%)
5 Best ETFs for the Rest of 2026

We look at five ETFs that can help investors leverage some of the trends expected to define the markets in the back half of the year.

CTVA : 78.67 (+0.46%)
JNJ : 257.59 (+1.04%)
TARS : 61.29 (+0.29%)
ABBV : 246.20 (+0.98%)
BOTZ : 37.30 (+0.57%)
MUFG : 22.42 (+2.70%)
HSBC : 102.68 (-3.17%)
NSRGY : 100.7000 (+0.75%)
XLB : 52.64 (+1.23%)
ASML : 1,678.22 (-1.97%)
LIN : 491.05 (+1.32%)
COLL : 35.74 (+0.03%)
Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston

STOUGHTON, Mass., July 20, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.  (Nasdaq: COLL) a leading biopharmaceutical company focused on improving the lives of people living with serious and...

COLL : 35.74 (+0.03%)
1 Healthcare Stock with Competitive Advantages and 2 We Question

1 Healthcare Stock with Competitive Advantages and 2 We Question

COLL : 35.74 (+0.03%)
IRTC : 124.50 (-2.07%)
AHCO : 6.49 (-3.20%)
1 Small-Cap Stock Worth Your Attention and 2 That Underwhelm

1 Small-Cap Stock Worth Your Attention and 2 That Underwhelm

COLL : 35.74 (+0.03%)
FOUR : 53.38 (-4.01%)
FLNC : 14.23 (-9.19%)
1 Mooning Stock to Own for Decades and 2 That Underwhelm

1 Mooning Stock to Own for Decades and 2 That Underwhelm

COLL : 35.74 (+0.03%)
TREX : 49.57 (+5.42%)
ALHC : 13.68 (+1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company's product candidate consists of COL-195, COL-196, COL-171,...

See More

Key Turning Points

3rd Resistance Point 37.30
2nd Resistance Point 36.86
1st Resistance Point 36.30
Last Price 35.74
1st Support Level 35.30
2nd Support Level 34.86
3rd Support Level 34.30

See More

52-Week High 50.79
Fibonacci 61.8% 42.73
Fibonacci 50% 40.24
Fibonacci 38.2% 37.76
Last Price 35.74
52-Week Low 29.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.